Amphastar Pharmaceuticals (AMPH) Downgraded by Zacks Investment Research to Strong Sell

Amphastar Pharmaceuticals} stock has undergone multiple analysts rating changes in the recent past.  Amphastar Pharmaceuticals Downgraded by Zacks Investment Research on 10/11/2021. In a note to investors, the firm issued a new rating of Strong Sell. The analysts previously had rating of Hold.

View More Amphastar Pharmaceuticals (AMPH) Downgraded by Zacks Investment Research to Strong Sell